Skip to main content

Table 5 Risk of SPM after lung HGNEC, stratified by age

From: Risk of second primary malignancy in adults with pulmonary high-grade neuroendocrine carcinoma (HGNEC)

  Observed Expected O/E 95% CI Excess risk
< 50 years
All Sites 31 8.26 3.75 2.55–5.33 87.27
All Solid Tumours 28 7.44 3.76 2.5–5.44 78.9
Oral cavity and pharynx 2 0.25 8.07 0.98–29.16 6.72
 Floor of Mouth 1 0.01 81.76 2.07–455.51 3.79
 Gum and Other Mouth 1 0.02 40.99 1.04–228.4 3.74
Digestive System 8 1.2 6.66 2.88–13.12 26.09
 Colon, Rectum and Anus 3 0.72 4.14 0.85–12.1 8.73
 Pancreas 5 0.12 41.88 13.6–97.74 18.73
Respiratory System 7 0.56 12.41 4.99–25.58 24.7
 Lung and Bronchus 7 0.49 14.22 5.72–29.3 24.97
Miscellaneous 2 0.09 21.21 2.57–76.62 7.31
50–64 years
All Sites 394 214.04 1.84 1.66–2.03 82.14
All Solid Tumours 361 194.61 1.86 1.67–2.06 75.95
Oral cavity and pharynx 13 6.26 2.08 1.11–3.55 3.08
 Floor of Mouth 3 0.37 8.13 1.68–23.76 1.2
 Pharynx 4 0.92 4.35 1.18–11.13 1.41
 Oropharynx 4 0.27 14.73 4.01–37.71 1.7
Digestive System 62 36.56 1.7 1.3–2.17 11.61
 Esophagus 7 2.14 3.27 1.31–6.73 2.22
 Small Intestine 4 1.04 3.83 1.04–9.81 1.35
 Ascending Colon 6 1.93 3.11 1.14–6.77 1.86
 Pancreas 17 4.97 3.42 1.99–5.48 5.49
Respiratory System 186 27.27 6.82 5.88–7.88 72.45
 Lung and Bronchus 180 24.94 7.22 6.2–8.35 70.77
Male Genital System 15 36.56 0.41 0.23–0.68 −9.84
 Prostate 14 36.09 0.39 0.21–0.65 −10.08
Urinary System 32 14.84 2.16 1.47–3.04 7.83
 Urinary Bladder 15 6.92 2.17 1.21–3.57 3.69
 Kidney 17 7.4 2.3 1.34–3.68 4.38
All Lymphatic and Hematopoietic Diseases 28 15.75 1.78 1.18–2.57 5.59
 Leukemia 24 4.52 5.32 3.41–7.91 8.89
 Acute Lymphocytic Leukemia 3 0.24 12.48 2.57–36.48 1.26
 Non-Lymphocytic Leukemia 18 2.08 8.67 5.14–13.7 7.27
 Acute Non-Lymphocytic Leukemia 16 1.36 11.75 6.72–19.08 6.68
 Myeloid and Monocytic Leukemia 18 1.94 9.29 5.51–14.68 7.33
 Acute Myeloid Leukemia 14 1.23 11.4 6.23–19.13 5.83
 Acute Monocytic Leukemia 2 0.08 24.43 2.96–88.23 0.88
> 65 years
All Sites 936 665.19 1.41 1.32–1.5 83.43
All Solid Tumours 852 588.37 1.45 1.35–1.55 81.22
Oral cavity and pharynx 15 13.55 1.11 0.62–1.83 0.45
 Floor of Mouth 4 0.73 5.48 1.49–14.04 1.01
Digestive System 157 127.41 1.23 1.05–1.44 9.12
 Colon, Rectum and Anus 97 67.29 1.44 1.17–1.76 9.15
 Colon and Rectum 91 65.22 1.4 1.12–1.71 7.94
 Colon excluding Rectum 77 49.1 1.57 1.24–1.96 8.6
 Ascending Colon 22 10.23 2.15 1.35–3.25 3.62
Respiratory System 457 117.15 3.9 3.55–4.28 104.7
 Lung and Bronchus 440 111.17 3.96 3.6–4.35 101.3
Breast 49 82.13 0.6 0.44–0.79 −10.21
Female Genital System 10 30.69 0.33 0.16–0.6 −6.37
 Corpus and Uterus, NOS 2 17.05 0.12 0.01–0.42 −4.64
Male Genital System 44 107.8 0.41 0.3–0.55 −19.65
 Prostate 43 106.87 0.4 0.29–0.54 −19.68
Urinary System 83 60.72 1.37 1.09–1.69 6.86
All Lymphatic and Hematopoietic Diseases 66 59.42 1.11 0.86–1.41 2.03
 Leukemia 42 18.82 2.23 1.61–3.02 7.14
 Non-Lymphocytic Leukemia 37 9.31 3.97 2.8–5.48 8.53
 Acute Non-Lymphocytic Leukemia 34 6.31 5.39 3.73–7.53 8.53
 Myeloid and Monocytic Leukemia 37 8.44 4.39 3.09–6.04 8.8
 Acute Myeloid Leukemia 32 5.66 5.65 3.87–7.98 8.11